NCT02231580View on ClinicalTrials.gov

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 1, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Huntington's Disease
Interventions
DRUG

BN82451B

BN82451B capsule

DRUG

Placebo

Placebo capsule

Trial Locations (1)

Unknown

Mönchengladbach

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY